OptiBiotix operates in the human microbiome market and we see the company at an interesting strategic inflection point, with developing revenues generated from its lead products and showing commercial traction with the next generation of products. We expect the company to generate value from both sets of products and see additional upside from its holding in SkinBioTherapeutics. With increasing interest being shown in targeting the human microbiome to improve health, OptiBiotix is well positione ....
06 Apr 2021
Cenkos: OptiBiotix Health Plc -- Major microbiome opportunities
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: OptiBiotix Health Plc -- Major microbiome opportunities
OptiBiotix Health PLC (OPTI:LON) | 18.0 -0.1 (-4.0%) | Mkt Cap: 17.6m
- Published:
06 Apr 2021 -
Author:
Chris Donnellan -
Pages:
50
OptiBiotix operates in the human microbiome market and we see the company at an interesting strategic inflection point, with developing revenues generated from its lead products and showing commercial traction with the next generation of products. We expect the company to generate value from both sets of products and see additional upside from its holding in SkinBioTherapeutics. With increasing interest being shown in targeting the human microbiome to improve health, OptiBiotix is well positione ....